Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes

 
• By Jo Shorthouse

Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.

Yacht
Seemingly plain sailing for ixelizumab in non-radiographic axial spondyloarthritis trial • Source: Shutterstock

More from Clinical Trials

More from R&D